EuroPCR 2017 Press Release: Low risk with deferred revascularisation based on measures of intracoronary physiology

Largest real-world dataset reports on deferred revascularisation in stable angina and ACS

Paris, France: Deferring revascularisation based on measures of intracoronary physiology using either instantaneous wave-free ratio (iFR) or fractional flow reserve (FFR) is associated with a low risk of major adverse coronary events, showed results reported at EuroPCR 2017 from the largest real-world study to investigate this strategy.

Functional intracoronary measurements with pressure guidewires assess how much a stenosis limits blood flow. They are currently used mainly in patients with coronary stenosis of intermediate severity. However, there is limited evidence on the safety of deferring revascularisation based on functional measurements in this subset of patients. Two recent large randomised clinical trials, DEFINE FLAIR and iFR SWEDEHEART, showed good outcomes in patients with intermediate stenosis undergoing physiology-guided revascularisation but did not report on patients where procedures were deferred.

The new analysis pooled patient-level data for the 4,529 patients enrolled in these two studies and looked at the impact of deferring procedures. Results showed that significantly fewer patients underwent interventions when iFR was used for decision making compared to FFR (50% vs. 45%, p=0.01).

The rate of major adverse cardiovascular events (MACE) was low in the 2,130 patients where myocardial revascularisation was deferred (4.12% with iFR and 4.05% with FFR at one year).

The event rate was higher in deferred patients who had acute coronary syndromes (ACS) than in those with stable coronary disease (SCD) (5.9% vs. 3.6%, p=0.04). Outcomes between ACS and SCD were significantly different when FFR was used for assessment (6.4% in ACS vs. 3.4% in SCD, p=0.049) but the difference was less marked when iFR was used (5.4% in ACS vs. 3.8% in SCD, p=0.37).

Deferral of myocardial revascularisation was associated with a higher rate of MACE in patients with acute coronary syndromes than in those with stable coronary disease,” said Escaned. He added, “The findings support the importance of further research into the physiological evaluation of patients with ACS.

Commenting on the study, Colin Berry, Professor of Cardiology and Imaging, University of Glasgow and Golden Jubilee National Hospital, UK, said, “Congratulations to the investigators! In ACS patients, invasive management reduces the risk of recurrent spontaneous MI and cardiac death, but these data are not reported in this meta-analysis, nor is the use of evidence-based medicines. This information would be helpful to better understand the results for translation to practice.

Contact information

Contact: Javier Escaned, Hospital Clinico San Carlos, Madrid, Spain
Email: escaned@secardiologia.es

Corresponding session

EuroPCR 2017 session: Tuesday 16 May 11:30-12:50, Hot Line/Late-breaking trials, Coronary interventions, interventions for valvular disease, left main and multivessel disease, NSTEMI, STEMI, Stents and scaffolds, TAVI; Main Arena

Help for journalists to cover EuroPCR 2017

 
For any press-related inquiries, please contact:

EuroPCR Press Coordinator, Isabelle Uzielli iuzielli@europcr.com

Register and attend EuroPCR 2017 as a journalist

Press registration for EuroPCR is open to accredited journalists, free of charge. Journalists must hold a valid press card and/or provide a letter of assignment from a recognised publication. To register as press go to
https://www.pcronline.com/Courses/EuroPCR/EuroPCR-2017/Press

EuroPCR press releases

EuroPCR press releases can be found at
https://www.pcronline.com/News/Press-releases?date=2017

 

Attend press briefings

For the press briefing schedule check
https://www.pcronline.com/Courses/EuroPCR/EuroPCR-2017/Press

EuroPCR abstracts

Abstracts are available online at
https://www.pcronline.com/Courses/EuroPCR/EuroPCR-2017

Notes to Editors

 
What is EuroPCR?

EuroPCR, the official annual meeting of the European Association for Percutaneous Cardiovascular Interventions (EAPCI), a registered branch of the European Society of Cardiology, is the world-leading course in interventional cardiovascular medicine. PCR has established a distinctive format for educational activities in the field of cardiovascular interventions. Beyond its flagship course in Paris that gathers more than 11,500 participants every year, PCR organises annual courses in Singapore, London UK, Dubai EAU, Johannesburg RSA, Milan Italy, Chengdu China and Tokyo Japan.

For further information on EuroPCR, PCR London Valves, PCR Peripheral, PCR-CIT China Chengdu Valves, GulfPCR-GIM, AsiaPCR, AfricaPCR, PCR Tokyo Valves, and all PCR activities, please contact: Célia Vilà: cvila@europa-organisation.com.

For more information, please visit: https://www.pcronline.com/Courses/EuroPCR/EuroPCR-2017 and follow us on Twitter https://twitter.com/PCRonline using the hashtag #EuroPCR